The 340B Drug Savings Program provides eligible providers, many of which are hospitals, with resources to maintain vital services in their communities and to provide additional services to their patients. A recent study published in the New England Journal of Medicine alleges that the 340B program does not expand access to care to low-income populations or improve their mortality rates, while driving hospital/physician consolidation.
340B Drug Pricing Program Blogs
Latest
It’s a new year but Congress has some old business to attend to—including many critical hospital and health system priorities. Both Houses of Congress will be back in session next week.
As early as next week, Congress could vote on a final tax reform bill. The House and Senate have each passed different versions, and now both houses have appointed conferees to shape the final bill. Now is the time to contact your legislators, especially if they are Republicans, and urge them to support AHA’s advocacy positions on issues critical to the field, including protecting the individual mandate, access to tax-exempt bond financing and the interest expense deduction for debt, among other items.
For 25 years, the 340B drug savings program, at no cost to the government, has enabled eligible hospitals to purchase certain outpatient drugs from pharmaceutical manufacturers at discounted prices
Millions of Americans worry about the high costs of life-saving prescription drugs.
The panel that advises the Centers for Medicare & Medicaid Services on hospital outpatient payments sent a clear signal to the agency this week: Don’t shortchange patients’ access to vital phar
The exorbitant cost of many prescription drugs threatens providers’ ability to provide life-saving medications for millions of Americans.
Every day, we see stories about the exorbitant costs of prescription drugs and the serious challenges they pose for individuals and the entire health care system.
A group financed by the pharmaceutical industry is hosting a meeting today on the 340B Drug Pricing Program with the goal of “Preserving the True Safety Net.” But what the meeting really will be ab
The rapidly rising costs of prescription drugs is causing significant financial challenges for patients and their care providers.
A July 6 Government Accountability Office (GAO) report examining Medicare Part B spending at hospitals participating in the 340B Drug Pricing Program draws unsubstantiated conclusions about a program that has a proven track record of improving access to care for poor patients and vulnerable communities. Simply put, the GAO report misses the mark.
A report paid for by a group backed by the pharmaceutical industry is the latest in a series of attempts to misrepresent a program that has a proven track record of helping poor patients and vulnerable communities.
A new report ;by the Berkley Research Group (BRG) is the latest attempt by the pharmaceutical industry to disparage a program with a proven track record of helping poor patients and vulnerable communities.
The 340B program accounts for only two percent of the $325 billion in annual drug purchases made in the U.S., or roughly $6.5 billion. Hospitals participating in the 340B program provided $28.4 billion in uncompensated care in 2012; in other words, four times the drug purchase amount.